Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares (ADS) of WPP plc, covering the period from February 27, 2025, to July 8, 2025, due to alleged misleading statements regarding the company's media arm [1][5]. Group 1: Lawsuit Details - The class action lawsuit has already been filed, and investors who purchased WPP plc ADSs during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5]. - Investors wishing to serve as lead plaintiffs must file their motion by December 8, 2025 [1][3]. Group 2: Allegations Against WPP - The complaint alleges that WPP provided overly positive statements while concealing material adverse facts about its media arm, which was reportedly unprepared for macroeconomic challenges and losing market share to competitors [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A securities class action lawsuit has been filed against KinderCare Learning Companies, Inc. alleging misleading statements during its October 2024 IPO, claiming that the company concealed a history of safety and care failures from investors [1][5]. Financial Performance - Since the IPO, KinderCare's stock has significantly declined from an offering price of $24 per share to lows near $9 per share, attributed to the market's realization of the company's unfounded positive statements [3]. Revenue Sources - More than 30% of KinderCare's revenues are derived from federal subsidies, making the alleged omissions regarding safety and care failures particularly significant, as they expose the company to undisclosed legal and regulatory risks [2]. Legal Investigation - Hagens Berman is investigating the claims against KinderCare, focusing on the alleged concealment of safety and care failures that may have led to an artificially inflated IPO price and subsequent investor losses [4][5]. Investor Communication - The firm encourages investors who purchased KLC stock in the IPO and suffered losses to consider their legal options, emphasizing the disconnect between KinderCare's presentation and the alleged reality of its operations [4][5].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Molina Healthcare, Inc. securities, alleging that the company failed to disclose material adverse facts during the Class Period from February 5, 2025, to July 23, 2025 [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Molina Healthcare did not disclose critical information regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - The lawsuit alleges that Molina's near-term growth relied on a lack of utilization of various health services, which was not communicated to investors [5]. - As a result of these undisclosed facts, Molina's financial guidance for fiscal year 2025 was likely to be significantly reduced, misleading investors about the company's business prospects [5]. Group 2: Participation Information - Investors who purchased Molina securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in terms of the number of securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Cytokinetics, Inc. common stock between December 27, 2023, and May 6, 2025, of the upcoming lead plaintiff deadline on November 17, 2025, for a class action lawsuit related to misleading statements about the company's drug approval process [1][5]. Group 1: Class Action Details - Investors who bought Cytokinetics common stock during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm or through their website [3][6]. - The lawsuit alleges that Cytokinetics made false statements regarding the timeline for the New Drug Application (NDA) submission and approval for aficamten, which misled investors about the regulatory process [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in recovering hundreds of millions of dollars for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Legal Action - Shareholders who purchased Agilon Health securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees, as the Rosen Law Firm prepares to seek recovery of investor losses [2]. - The investigation follows a significant stock price drop of 51.5% on August 5, 2025, after Agilon Health suspended its full-year 2025 financial guidance, citing more acute industry headwinds than previously expected [3]. Group 2: Company Performance and Financial Guidance - On August 4, 2025, Agilon Health reported its second-quarter results and indicated that it was suspending its previously issued financial guidance for the full year 2025 [3].

Core Viewpoint - A securities class action lawsuit has been filed against aTyr Pharma, Inc. for allegedly disseminating false and misleading statements regarding the efficacy of its drug Efzofitimod during a clinical trial [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased aTyr Pharma common stock between January 16, 2025, and September 12, 2025, with a lead plaintiff deadline set for December 8, 2025 [1][6]. - The complaint claims that aTyr Pharma concealed material adverse facts about Efzofitimod's ability to allow patients to taper steroid usage [3]. Group 2: Clinical Trial Results - aTyr Pharma conducted a Phase 3 study (EFZO-FIT) to evaluate Efzofitimod's safety and efficacy in patients with pulmonary sarcoidosis [3]. - On September 15, 2025, aTyr Pharma announced that the EFZO-FIT study failed to meet its primary endpoint regarding the reduction of mean daily oral corticosteroid dose at week 48 [4]. Group 3: Stock Price Impact - Following the announcement of the disappointing trial results, aTyr Pharma's stock price plummeted by 83.2%, dropping from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025 [5]. Group 4: Legal Representation - Investors affected by the stock price decline are encouraged to contact Shamis & Gentile, P.A. for information on seeking recovery claims [2][6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RCI Hospitality Holdings, Inc. between December 15, 2021, and September 16, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased RCI Hospitality securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is November 20, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]. Group 3: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements, engaged in tax fraud, and committed bribery to cover up the fraud [5]. - It is claimed that these actions resulted in an understatement of the legal risks facing RCI Hospitality, leading to misleading statements about the company's business and operations [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of KinderCare Learning Companies, Inc. about the upcoming lead plaintiff deadline for a class action lawsuit related to the company's October 2024 IPO [1] Group 1: Class Action Details - Investors who purchased KinderCare common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 14, 2025 [3] - The lawsuit claims that the registration statement was false and/or misleading, failing to disclose incidents of child abuse and neglect at KinderCare facilities, and that the company did not meet minimum care standards [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been ranked highly for its securities class action settlements [4]

Core Viewpoint - Tronox Holdings plc (NYSE: TROX) is facing a class action lawsuit due to allegations of misleading statements regarding its financial performance and demand forecasting for its products, leading to a significant drop in stock price [1][2]. Summary by Sections Allegations - The complaint claims that Tronox provided overly positive statements while concealing material adverse facts about its commercial division and demand forecasting capabilities [1]. - Despite ambitious long-term projections, Tronox's sales continued to decline, and costs increased, which ultimately affected revenue projections [1]. - On July 30, 2025, Tronox reported a significant reduction in TiO2 sales, attributing the decline to a weaker coatings season and increased competition [1]. Financial Impact - Following the announcement of poor financial results, Tronox revised its 2025 financial outlook, lowering full-year revenue guidance and cutting its dividend by 60% [1]. - The stock price plummeted from $5.14 per share on July 30, 2025, to $3.19 per share on July 31, 2025, marking a decline of approximately 38% in one day [1]. Next Steps for Shareholders - Shareholders who purchased shares during the specified class period are encouraged to register for the class action by November 3, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2].

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of KinderCare Learning Companies, Inc. (NYSE: KLC) pursuant and/or traceable to the registration statement issued in connection with KinderCare’s October 2024 initial public offering (the “IPO”), of the important October 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased KinderCare common stock you may be entitled to compensation without payment of any out of pocke ...